QQQ   358.87 (+0.28%)
AAPL   175.35 (+0.82%)
MSFT   317.72 (-0.57%)
META   299.91 (+1.41%)
GOOGL   130.58 (+0.11%)
AMZN   129.34 (+0.01%)
TSLA   247.93 (-3.04%)
NVDA   414.92 (+1.16%)
NIO   8.50 (+0.59%)
BABA   88.11 (+4.76%)
AMD   96.17 (+0.06%)
T   15.18 (-0.85%)
F   12.50 (+2.46%)
MU   69.10 (+1.77%)
CGC   0.82 (+6.36%)
GE   112.04 (-0.84%)
DIS   81.73 (-1.21%)
AMC   7.76 (+0.78%)
PFE   32.64 (-0.64%)
PYPL   58.06 (-0.96%)
NFLX   379.45 (-1.22%)
QQQ   358.87 (+0.28%)
AAPL   175.35 (+0.82%)
MSFT   317.72 (-0.57%)
META   299.91 (+1.41%)
GOOGL   130.58 (+0.11%)
AMZN   129.34 (+0.01%)
TSLA   247.93 (-3.04%)
NVDA   414.92 (+1.16%)
NIO   8.50 (+0.59%)
BABA   88.11 (+4.76%)
AMD   96.17 (+0.06%)
T   15.18 (-0.85%)
F   12.50 (+2.46%)
MU   69.10 (+1.77%)
CGC   0.82 (+6.36%)
GE   112.04 (-0.84%)
DIS   81.73 (-1.21%)
AMC   7.76 (+0.78%)
PFE   32.64 (-0.64%)
PYPL   58.06 (-0.96%)
NFLX   379.45 (-1.22%)
QQQ   358.87 (+0.28%)
AAPL   175.35 (+0.82%)
MSFT   317.72 (-0.57%)
META   299.91 (+1.41%)
GOOGL   130.58 (+0.11%)
AMZN   129.34 (+0.01%)
TSLA   247.93 (-3.04%)
NVDA   414.92 (+1.16%)
NIO   8.50 (+0.59%)
BABA   88.11 (+4.76%)
AMD   96.17 (+0.06%)
T   15.18 (-0.85%)
F   12.50 (+2.46%)
MU   69.10 (+1.77%)
CGC   0.82 (+6.36%)
GE   112.04 (-0.84%)
DIS   81.73 (-1.21%)
AMC   7.76 (+0.78%)
PFE   32.64 (-0.64%)
PYPL   58.06 (-0.96%)
NFLX   379.45 (-1.22%)
QQQ   358.87 (+0.28%)
AAPL   175.35 (+0.82%)
MSFT   317.72 (-0.57%)
META   299.91 (+1.41%)
GOOGL   130.58 (+0.11%)
AMZN   129.34 (+0.01%)
TSLA   247.93 (-3.04%)
NVDA   414.92 (+1.16%)
NIO   8.50 (+0.59%)
BABA   88.11 (+4.76%)
AMD   96.17 (+0.06%)
T   15.18 (-0.85%)
F   12.50 (+2.46%)
MU   69.10 (+1.77%)
CGC   0.82 (+6.36%)
GE   112.04 (-0.84%)
DIS   81.73 (-1.21%)
AMC   7.76 (+0.78%)
PFE   32.64 (-0.64%)
PYPL   58.06 (-0.96%)
NFLX   379.45 (-1.22%)

IDEAYA Biosciences (IDYA) Stock Forecast, Price & News

$27.71
-0.48 (-1.70%)
(As of 02:10 PM ET)
Compare
Today's Range
$27.68
$28.29
50-Day Range
$21.07
$29.77
52-Week Range
$11.04
$30.25
Volume
126,298 shs
Average Volume
539,049 shs
Market Capitalization
$1.59 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.08

IDEAYA Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
15.8% Upside
$32.08 Price Target
Short Interest
Bearish
13.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.88mentions of IDEAYA Biosciences in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$827,735 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.01) to ($2.61) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

510th out of 968 stocks

Pharmaceutical Preparations Industry

221st out of 445 stocks


IDYA stock logo

About IDEAYA Biosciences (NASDAQ:IDYA) Stock

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase II clinical trial for patients with solid tumors having methylthioadenosine phosphorylase gene deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester todevelop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase II/III study in metastatic uveal melanoma, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

IDYA Price History

IDYA Stock News Headlines

Bringing Space Down to Earth
Cutting edge, AI-powered, Space-based Earth-observation solutions
IDEAYA Biosciences (NASDAQ:IDYA) Price Target Raised to $37.00
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
7 Analysts Have This to Say About IDEAYA Biosciences
Stifel Nicolaus Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)
The Latest Analyst Ratings for IDEAYA Biosciences
See More Headlines
Receive IDYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IDYA Company Calendar

Last Earnings
8/10/2023
Today
9/22/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IDYA
Fax
N/A
Employees
116
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$32.08
High Stock Price Forecast
$43.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+13.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
14 Analysts

Profitability

Net Income
$-58,650,000.00
Net Margins
-164.25%
Pretax Margin
-164.25%

Debt

Sales & Book Value

Annual Sales
$50.93 million
Book Value
$7.26 per share

Miscellaneous

Free Float
54,623,000
Market Cap
$1.62 billion
Optionable
Not Optionable
Beta
0.75
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Yujiro S. Hata (Age 49)
    Co-Founder, Pres, CEO & Director
    Comp: $851.7k
  • Dr. Michael A. White Ph.D. (Age 57)
    Chief Scientific Officer
    Comp: $613.85k
  • Dr. Darrin M. Beaupre M.D. (Age 56)
    Ph.D., Chief Medical Officer
    Comp: $152.64k
  • Dr. Jeffrey Hager Ph.D. (Age 58)
    Co -Founder
  • Mr. Paul A. Stone J.D.Mr. Paul A. Stone J.D. (Age 59)
    Chief Financial Officer
  • Mr. Andres Ruiz Briseno CPA (Age 37)
    Principal Accounting Officer, Sr. VP and Head of Fin. & Investor Relations
  • Dr. Paul A. Barsanti Ph.D.
    Chief Technology Officer
  • Mr. Jason S. Throne Esq. (Age 51)
    J.D., Chief Legal Officer & Company Sec.
  • Dr. Matthew Maurer M.D.
    VP and Head of Medical Affairs & Clinical Oncology
  • Mr. Mick O'Quigley
    Sr. VP of Devel. Operations













IDYA Stock - Frequently Asked Questions

Should I buy or sell IDEAYA Biosciences stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last year. There are currently 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IDYA shares.
View IDYA analyst ratings
or view top-rated stocks.

What is IDEAYA Biosciences' stock price forecast for 2023?

14 equities research analysts have issued 1 year price targets for IDEAYA Biosciences' shares. Their IDYA share price forecasts range from $24.00 to $43.00. On average, they predict the company's share price to reach $32.08 in the next year. This suggests a possible upside of 13.8% from the stock's current price.
View analysts price targets for IDYA
or view top-rated stocks among Wall Street analysts.

How have IDYA shares performed in 2023?

IDEAYA Biosciences' stock was trading at $18.17 at the beginning of the year. Since then, IDYA shares have increased by 55.1% and is now trading at $28.19.
View the best growth stocks for 2023 here
.

When is IDEAYA Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our IDYA earnings forecast
.

How were IDEAYA Biosciences' earnings last quarter?

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) issued its quarterly earnings data on Thursday, August, 10th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.05. The company earned $3.50 million during the quarter, compared to the consensus estimate of $4.89 million. IDEAYA Biosciences had a negative net margin of 164.25% and a negative trailing twelve-month return on equity of 19.09%. The business's revenue for the quarter was down 55.7% on a year-over-year basis.

What ETFs hold IDEAYA Biosciences' stock?

ETFs with the largest weight of IDEAYA Biosciences (NASDAQ:IDYA) stock in their portfolio include Jacob Forward ETF (JFWD), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and ALPS Medical Breakthroughs ETF (SBIO).iShares Micro-Cap ETF (IWC).

What other stocks do shareholders of IDEAYA Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Boeing (BA), Xeris Biopharma (XERS), Entasis Therapeutics (ETTX), Livongo Health (LVGO) and NVIDIA (NVDA).

When did IDEAYA Biosciences IPO?

(IDYA) raised $70 million in an initial public offering on Thursday, May 23rd 2019. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies served as the underwriters for the IPO.

What is IDEAYA Biosciences' stock symbol?

IDEAYA Biosciences trades on the NASDAQ under the ticker symbol "IDYA."

Who are IDEAYA Biosciences' major shareholders?

IDEAYA Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (9.87%), BlackRock Inc. (7.60%), State Street Corp (3.72%), Dimensional Fund Advisors LP (1.90%), Geode Capital Management LLC (1.79%) and Platinum Investment Management Ltd. (1.42%). Insiders that own company stock include Jason Throne, Mark Lackner, Michael P Dillon, Michael P Dillon, Paul A Stone and Ventures Iv LP 5Am.
View institutional ownership trends
.

How do I buy shares of IDEAYA Biosciences?

Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IDEAYA Biosciences' stock price today?

One share of IDYA stock can currently be purchased for approximately $28.19.

How much money does IDEAYA Biosciences make?

IDEAYA Biosciences (NASDAQ:IDYA) has a market capitalization of $1.62 billion and generates $50.93 million in revenue each year. The company earns $-58,650,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis.

How many employees does IDEAYA Biosciences have?

The company employs 116 workers across the globe.

How can I contact IDEAYA Biosciences?

IDEAYA Biosciences' mailing address is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.ideayabio.com. The company can be reached via phone at (650) 443-6209 or via email at investor@ideayabio.com.

This page (NASDAQ:IDYA) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -